Microbiology SpectrumMicrobiologyPeer-reviewed journal article
Investigating Novel Streptomyces Bacteriophage Endolysins as Potential Antimicrobial Agents
Jindanuch ManeekuliD, Amanda Chiaha, Rachel L. HughesiD, Faith LabryiD, Joshua Saito, Matthew Almendares, Brenda N. Banda, L.R. López y López, Nyeomi McGaskey, Melizza Miranda, Jenil Rana, Brandon R. Zadeh, Lee E. HughesiD
- Citations
- 3
- FWCI
- 0.46
- Field percentile
- top 42%
Abstract
BackgroundAs antibiotic resistance has become a major global threat; the World Health Organization (WHO) has urgently called for alternative strategies for control of bacterial infections. Endolysin, a phage-encoded protein, can degrade bacterial peptidoglycan (PG) and disrupt bacterial growth. According to the WHO, there are only three endolysin products currently in clinical phase development. In this study we explore novel endolysins from Streptomyces phages as only a few of them have been experimentally characterized. Using several bioinformatics tools, we identified nine different functional domain combinations from 250 Streptomyces phages putative endolysins. LazerLemon gp35 (CHAP; LL35lys), Nabi gp26 (amidase; Nb26lys), and Tribute gp42 (PGRP/amidase; Tb42lys) were selected for experimental studies. We hypothesized that (1) the proteins of interest will have the ability to degrade purified PG, and (2) the proteins will have potential antimicrobial activity against bacteria from families of importance in antibiotic resistance, such as ESKAPE safe relatives (Enterococcus raffinosus, Staphylococcus epidermidis, Klebsiella aerogenes, Acinetobacter baylyi, Pseudomonas putida, and Escherichia coli). ResultsLL35lys, Nb26lys, and Tb42lys exhibit PG-degrading activity on zymography and hydrolysis assay. The enzymes (100 {micro}g/mL) can reduce PG turbidity to 32-40%. The killing assay suggests that Tb42lys has a broader range (E. coli, P. putida, A. baylyi and K. aerogenes). While Nb26lys better attacks Gram-negative than Gram-positive bacteria, LL35lys can only reduce the growth of the Gram-positive ESKAPE strains but does so effectively with a low MIC90 of 2 {micro}g/mL. A higher concentration ([≥]300 {micro}g/mL) of Nb26lys is needed to inhibit P. putida and K. aerogenes. ConclusionFrom 250 putative endolysins, bioinformatic methods were used to select three putative endolysins for cloning and study: LL35lys, Nb26lys, and Tb42lys. All have shown PG-degrading activity, a critical function of endolysin. With a low MIC, LL35lys shows activity for the Gram-positive ESKAPE strains, while Nb26lys and Tb42lys are active against the Gram-negatives. Therefore, endolysins from Streptomyces phage have potential as possible antimicrobial agents against ESKAPE bacteria.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Lysozyme Murein Hydrolase with Broad-spectrum Antibacterial Activity from Enterobacter Phage myPSH1140
R. Nachimuthu, P. Manohar, … S. Leptihn·bioRxiv·Apr 6, 2022
- Novel Bacillus altitudinis endolysin (ArtE2) targeting both Gram-positive and Gram-negative bacteria
Roxana Portieles, Xinmin Ma, … Orlando Borrás‐Hidalgo·bioRxiv·Jan 22, 2026
- Sequence-function relationships in phage-encoded bacterial cell wall lytic enzymes and their implications for phage-derived products design
R. Vazquez, E. Garcia, P. Garcia·bioRxiv·Feb 23, 2021
- Innolysins: A novel approach to engineer endolysins to kill Gram-negative bacteria
Athina Zampara, Martine C. Holst Sørensen, … Lone Brøndsted·bioRxiv·Sep 6, 2018
- Antibacterial activity of a newly identified phage-derived endolysin and its parental bacteriophage against clinical uropathogenic Escherichia coli
Wojciech Wesołowski, Sylwia Bloch, … Bożena Nejman-Faleńczyk·bioRxiv·Sep 10, 2026
- Unlocking prophage potential: In silico and experimental analysis of a novel Mycobacterium fortuitum LysinB containing a peptidoglycan-binding domain
Ritam Das, Kanika Nadar, … Urmi Bajpai·bioRxiv·Feb 15, 2024